Role of sodium glucose cotransporter-2 (SGLT2) inhibitors in the modulation of QTc interval and ventricular arrhythmia in patients with diabetes mellitus combined with hypertension and coronary artery disease.

SGLT2 inhibitors produced lower QTc intervals compared to conventional therapy alone in patients with diabetes mellitus combined with hypertension and coronary artery disease.

• 150 patients with DM-HTN-CAD were selected from January 2023 to January 2025
• Patients were divided into a conventional treatment group and an SGLT2 inhibitor group
• The SGLT2 inhibitors group received SGLT2 inhibitor treatment in addition to conventional treatment
• After treatment, QTc interval differences between groups were statistically significant (P<0.05)
• No baseline differences were observed between the two groups prior to treatment (P>0.05)

SGLT2 inhibitor treatment was associated with reductions in cardiac chamber dimensions including left and right atrial diameters and left and right ventricular diameters.

• Echocardiographic parameters measured included left and right ventricular diameter, left and right atrial diameter, and ejection fraction
• All cardiac chamber dimensions were lower in the SGLT2 inhibitors group compared to the conventional therapy group after treatment (P<0.05)
• Both groups showed significant changes in these parameters compared to pre-treatment values (P<0.05)

Left ventricular ejection fraction was higher in the SGLT2 inhibitors group compared to the conventional treatment group after treatment.

• Left ventricular ejection fraction was among the main echocardiographic indicators compared between groups
• The difference in ejection fraction between groups after treatment was statistically significant (P<0.05)
• Both groups showed improvement in ejection fraction compared to pre-treatment values (P<0.05)

SGLT2 inhibitors produced greater reductions in blood pressure and fasting blood glucose compared to conventional therapy.

• Systolic blood pressure, diastolic blood pressure, and fasting blood glucose levels were all lower in the SGLT2 inhibitors group compared to the conventional therapy group (P<0.05)
• Blood pressure and glucose indicators were classified as main indicators in the study
• Both groups showed significant changes in these parameters compared to pre-treatment (P<0.05)

Patients in the SGLT2 inhibitors group had higher quality of life scores and overall clinical response rates than those receiving conventional treatment alone.

• Quality of life scores were higher in the SGLT2 inhibitors group compared to the conventional therapy group (P<0.05)
• Overall clinical response rates were higher in the SGLT2 inhibitors group (P<0.05)
• Quality of life scores and clinical response rates were classified as secondary indicators

The incidence of complications and adverse reactions was lower in the SGLT2 inhibitors group compared to the conventional treatment group.

• Complications and adverse reaction incidences were among the secondary indicators assessed
• Both complications and adverse reactions were lower in the SGLT2 inhibitors group (P<0.05)
• The authors described the safety profile of SGLT2 inhibitors as 'favorable'